Attralus Overview

  • Founded
  • 2019
Founded
  • Status
  • Private
  • Employees
  • 13
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $116M
Latest Deal Amount
  • Investors
  • 12

Attralus General Information

Description

Developer of immunotherapies and an imaging diagnostic platform designed for multiple systemic amyloid disease treatment. The company specializes in the research and development of immunotherapies to clear amyloid fibrils in patients with systemic amyloid diseases, like a light chain(AL), transthyretin (ATTR), and LECT2 (ALECT2) amyloidosis, enabling the healthcare industry to treat amyloidosis patients in an efficient manner.

Contact Information

Website
www.attralus.com
Formerly Known As
Aurora Bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 329 Oyster Point Boulevard
  • 3rd Floor
  • South San Francisco, CA 94080
  • United States
+1 (415) 000-0000

Attralus Timeline

202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Attralus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 08-Sep-2021 $116M 00000 00000 Completed Clinical Trials - General
2. Early Stage VC (Series A) 14-Sep-2020 000.00 000.00 000.00 Completed Clinical Trials - General
1. Accelerator/Incubator 08-Nov-2019 Completed Clinical Trials - General
To view Attralus’s complete valuation and funding history, request access »

Attralus Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.00
To view Attralus’s complete cap table history, request access »

Attralus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of immunotherapies and an imaging diagnostic platform designed for multiple systemic amyloid disease treatment
Drug Discovery
South San Francisco, CA
13 As of 2021
00000
0000 0000-00-00
00000000000 00000

0000000

ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor i
0000 000000000
Cambridge, MA
0000 As of 0000
00.000
0000 00.000

00000000

im veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis a
0000000000000
San Diego, CA
000 As of 0000
00000
000000000 - 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Attralus Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
000000 00000000000 Venture Capital-Backed Bordentown, NJ 000.00 000000&0 000.00
000 0000000 Venture Capital-Backed Barcelona, Spain 00 000.00 00000 00000 000.00
To view Attralus’s complete competitors history, request access »

Attralus Executive Team (6)

Name Title Board Seat Contact Info
Benson Fong Chief Financial Officer
Spencer Guthrie Co-Founder & Chief Operating Officer
Jonathan Wall Ph.D Co-Founder & Interim Chief Scientific Officer
Glen Firestone Chief Business Officer
Gregory Bell MD Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Attralus Board Members (7)

Name Representing Role Since
Alexander Denner Ph.D Sarissa Capital Management Board Member 000 0000
Corey Goodman Ph.D venBio Chairman 000 0000
Jacob Bauer Self Board Member 000 0000
Mark Timney Self Chief Executive Officer & Board Member 000 0000
Nancy Miller-Rich Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Attralus Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Attralus Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Citadel (Hedge Fund) Hedge Fund Minority 000 0000 000000 0
Janus Henderson Investors Asset Manager Minority 000 0000 000000 0
LifeSci Venture Partners Corporate Venture Capital Minority 000 0000 000000 0
Logos Capital Hedge Fund Minority 000 0000 000000 0
Redmile Group Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial